drugset / Trial / NCT05594303

COPD Treatment by Transplantation of Autologous Bronchial Basal Cells

NCT05594303 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Chronic obstructive pulmonary disease (COPD) is a group of disease characterized by obstructed airflow. Usually, the lung structure is gradually impaired along with the progression of the disease. Recently, the treatment of disease is challenged by shortage of approaches for regenerating the injured lung tissue. Here in this study, investigators intend to perform a single-centered, open, concurrent-controlled phase I/II clinical trial with autologous bronchial basal cells on COPD treatment since they were proved to regenerate lung tissue in animal models. The participants is recruited and divided into experiment group and control group. For patients from experiment group, bronchial basal cells will be isolated, expanded, carefully characterized in vitro and transplanted autologously into lung by fiberoptic bronchoscopy. No intervention is performed for patients from control group. During the study, the safety and efficacy will be evaluated on all the subjects by measuring the key indicators.

Timeline

Start
2019-11-27
Primary completion
2022-05-16
Completion
2022-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Bronchial basal cells Cell therapy — Other